

A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 - Pipeline Review, H2 2019

<https://marketpublishers.com/r/A149AC82BB2CEN.html>

Date: December 2019

Pages: 65

Price: US\$ 3,500.00 (Single User License)

ID: A149AC82BB2CEN

Abstracts

A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 - Pipeline Review, H2 2019

SUMMARY

According to the recently published report 'A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 - Pipeline Review, H2 2019'; A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) pipeline Target constitutes close to 7 molecules.

A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) - A disintegrin and metalloproteinase with thrombospondin motifs 5 or ADAMTS5 is an enzyme encoded by the ADAMTS5 gene. It plays an important role in the destruction of aggrecan in arthritic diseases and in proteolytic processing mostly during the peri-implantation period.

The report 'A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 - Pipeline Review, H2 2019' outlays comprehensive information on the A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I and Preclinical stages are 2, 1 and 4 respectively. Report covers products from therapy areas Musculoskeletal Disorders, Cardiovascular, Central Nervous System, Genetic Disorders, Infectious Disease and Respiratory which include indications Osteoarthritis, Knee Osteoarthritis, Allergic Asthma, Alphavirus Infections, Arthralgia (Joint Pain), Arthritis, Chikungunya Fever, Congestive Heart Failure (Heart Failure), Edema, Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) and Seasonal Allergic Rhinitis.

SCOPE

The report provides a snapshot of the global therapeutic landscape for A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.)

The report reviews A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) targeted therapeutics and enlists all their major and minor projects

The report assesses A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or

Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) - Overview

A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) - Companies Involved in Therapeutics Development

Eli Lilly and Co

Galapagos NV

GlaxoSmithKline Plc

Merck KGaA

Paradigm Biopharmaceuticals Ltd

Ribomic Inc

Rottapharm Biotech Srl

A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) - Drug Profiles

CRB-0017 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GLPG-1972 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-2394002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

M-6495 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pentosan polysulfate sodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RBM-010 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit ADAMTS4 and ADAMTS5 for Osteoarthritis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) - Dormant Products

A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) - Product Development Milestones

Featured News & Press Releases

Sep 30, 2019: Peer-reviewed publication confirms Paradigms ground-breaking discovery regarding new MOA for PPS

Sep 10, 2019: Paradigms first FDA IND is cleared within the 30-day review period

Aug 29, 2019: Paradigm discovers Zilosulo (iPPS) protects cartilage in knee osteoarthritis

Jun 11, 2019: Servier and Galapagos complete enrollment of global ROCCELLA Phase 2 clinical trial with GLPG1972/S201086 in knee osteoarthritis patients

Jun 04, 2019: Paradigm reports successful ross river phase 2a clinical trial

May 28, 2019: Paradigm reports positive RWE data for knee osteoarthritis therapeutic

Apr 16, 2019: Paradigm's knee osteoarthritis study meets secondary endpoints

Feb 14, 2019: Paradigm's orphan phase 2/3 clinical program progresses

Nov 27, 2018: Galapagos receives Fast Track designation from FDA for GLPG1972/S201086 in osteoarthritis

Nov 07, 2018: Paradigms Osteoarthritis treatment maintains more than 50% knee pain reduction

Sep 25, 2018: Galapagos doses first patient in Phase II trial of GLPG1972/S201086

Sep 25, 2018: Paradigm consistently shows greater than 50% knee pain reduction

Aug 28, 2018: Paradigm's phase 2 a Ross River virus clinical trial recruitment finalised

Aug 15, 2018: Paradigm achieves 60% reduction in osteoarthritis pain

Aug 06, 2018: Paradigm achieves 100% recruitment in Phase 2b Osteoarthritis Trial

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Indication, H2 2019

Number of Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Pipeline by Eli Lilly and Co, H2 2019

Pipeline by Galapagos NV, H2 2019

Pipeline by GlaxoSmithKline Plc, H2 2019

Pipeline by Merck KGaA, H2 2019

Pipeline by Paradigm Biopharmaceuticals Ltd, H2 2019

Pipeline by Ribomic Inc, H2 2019

Pipeline by Rottapharm Biotech Srl, H2 2019

Dormant Projects, H2 2019

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019

COMPANIES MENTIONED

Eli Lilly and Co

Galapagos NV

GlaxoSmithKline Plc

Merck KGaA

Paradigm Biopharmaceuticals Ltd

Ribomic Inc

Rottapharm Biotech Srl

I would like to order

Product name: A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/A149AC82BB2CEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A149AC82BB2CEN.html>